Digestive System
Conditions
Interventions
Empagliflozin
Control
Sponsors
None
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years old or older. 2. Decompensated liver cirrhosis complicated with ascites. 3.Ability to understand and willingness to participate and sign a written informed consent document
Exclusion criteria
Exclusion criteria: 1.age under 18 years old; 2.History of any attack of hypoglycemia (defined as serum glucose less than 70 mg/dl) either symptomatic or a symptomatic. 3.vitally unstable pt 4.Patients who receive non-selective B-blockers. 5.History of recurrent urinary tract infection defined as more than 2 infections in last 6 months 6.Pregnancy and breast feeding 7.History of hypersensitivity to any SGLT2 inhibitor 8.Presence of hepatocellular carcinoma or any other malignancy. 9.eGFR below 45mL/min/1.73m2 or decrease in eGFR by >30% between screening 10. Patients with history of diabetes mellitus complicated with diabetic ketoacidosis (DKA) or patients have any risk factors for DKA 12. History of alcohol intake
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1- Efficacy of empagliflozin in the management of hepatic ascites improvement in the form of decreased ascites by clinical follow-up and periodic abdominal ultrasound examination, weight assessment, and urine output. 2- side effects of empagliflozin including hypoglycemia, hepatic deterioration, increased ascites, urinary tract infection, and any other adverse effects. | — |
Secondary
| Measure | Time frame |
|---|---|
| subgroup analyis according to age, sex, garde of hepatic decompenation and any other beficail subgroup analyisis. | — |
Countries
Egypt
Contacts
Public ContactKhaled AbdelAzeem
Professor of Hepatology gastroenterology and infectious diseases AlAzhar University Assiut Egypt
Outcome results
None listed